CROMA at ESCRS

Article

During this year?s ESCRS in Vienna CROMA will highlight its history of 35 years as a key player in ophthalmology.

During this year´s ESCRS in Vienna CROMA will highlight its history of 35 years as a key player in ophthalmology. Having started from a small pharmacy, the family-owned company reached the level of big international competitors, constantly developing innovative and unique products for markets all over the world.

Currently, CROMA is performing clinical studies, involving a new product, based on the so-called Thiomers, a unique technology combining macromolecules such as hyaluronic acid to a human amino acid (cysteine) for different ophthalmic applications. First results will be presented during the CROMA satellite symposium.

In the field of intraocular lenses, CROMA is launching two new models in 2011. The new hydrophobic blue-light filtering IOL “EYE-Cee One” has been successfully introduced in May. First clinical experiences will be shared during the ESCRS lunch symposium. CROMA will further make use of the ESCRS in Vienna to internationally launch its new multifocal IOL.

CROMA satellite symposium:

“Amazing Advances in Ocular Excellence”
Sunday, 18th September, 2011
1:00 pm – 2:00 pm
Room Stolz 1

CROMA - Bausch and Lomb joint satellite symposium:

“Bromfenac, a new potent Tool in Inflammation Control post cararact surgery”
Sunday, 18th September, 2011
1:00 pm – 2:00 pm
Room Strauss 3

Click here to register online.

Click here to email CROMA

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.